CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Intralipid/Heparin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02517307
NCT02517307N/ACompleted
CompareCT.gov

Role of Fatty Acid Oxidation Defects in Insulin Sensitivity

Oregon Health and Science University·interventional·Posted Aug 7, 2015·Updated Jan 30, 2024

In Brief

A clinical study evaluating Intralipid/Heparin, Glycerol/Saline, and 1 other intervention for Very Long-chain Acyl-CoA Dehydrogenase Deficiency and 5 related conditions. Completed, enrolled 41 participants across 1 site.

Detailed Summary

The purpose of this study is to learn more about what causes insulin resistance. It has been suggested that proper breakdown of fat into energy (oxidation) in the body is important to allow insulin to keep blood sugar in the normal range. The investigators want to know if having one of the fatty acid oxidation disorders could have an influence on insulin action. Fatty acid oxidation disorders are genetic disorders that inhibit one of the enzymes that converts fat into energy. The investigators will study both normal healthy people and people with a long-chain fatty acid oxidation disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVery Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 7, 2015
Enrollment StartFeb 1, 2016
Primary CompletionJan 1, 2021
Study CompletionMar 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 10.9 years ago

Interventions

Intralipid/Heparindrug

Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp

Glycerol/Salinedrug

Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp

Hyperinsulinemic euglycemic clampdrug

Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.